Xenon Announces Appointment of Ian C. Mortimer as Chief Financial Officer
VANCOUVER, British Columbia, Sept. 10, 2013 /CNW/ - Xenon Pharmaceuticals Inc.
is pleased to announce the appointment of Mr. Ian C. Mortimer as Chief
"We are delighted to welcome Ian to the Xenon team," said Dr. Simon Pimstone,
Xenon's President and CEO. "Ian brings a combination of strong financial and
operations experience that is highly relevant to Xenon. Given our pipeline of
approved, development stage and discovery stage products and programs,
together with our strong balance sheet and our suite of major pharmaceutical
partnerships, this is a good time for Xenon to be adding an experienced CFO
like Ian to the company."
Mr. Mortimer has over 15 years experience in the biotechnology sector. He is
currently Executive Vice President and Chief Financial Officer at Tekmira
Pharmaceuticals Corporation (Tekmira), a Nasdaq-listed biotechnology company
focused on advancing RNAi therapeutic products. Mr. Mortimer is responsible
for all aspects of Tekmira's finance and capital markets activities and led
Tekmira's listing on Nasdaq in 2010. Prior to his most recent position at
Tekmira, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals
Corporation. Mr. Mortimer has an MBA from Queen's University, a B.Sc. in
Microbiology from the University of British Columbia and is a Certified
Management Accountant. Mr. Mortimer will join Xenon as Chief Financial
Officer full time by November 1, 2013.
About Xenon Pharmaceuticals Inc. Xenon is a privately owned biopharmaceutical
company focused on the development of novel medicines through the application
of our proprietary discovery platform, which we refer to as Extreme Genetics.
We are developing proprietary product candidates for the treatment of both
orphan as well as more prevalent diseases. For more information, visit the
Company's website at http://www.xenon-pharma.com.
This release contains forward-looking statements that are not based on
historical fact. These forward-looking statements involve risks, uncertainties
and other factors that may cause the actual results, events or developments to
be materially different from those expressed or implied by such
forward-looking statements. Readers are cautioned not to place undue reliance
on such forward-looking statements.
SOURCE Xenon Pharmaceuticals Inc.
Dr. Simon Pimstone, President & CEO, +1-604-484-3300, firstname.lastname@example.org
To view this news release in HTML formatting, please use the following URL:
CO: Xenon Pharmaceuticals Inc.
ST: British Columbia
NI: HEA MTC BTC 2575 WNEWS
-0- Sep/10/2013 10:05 GMT
Press spacebar to pause and continue. Press esc to stop.